SERPINA4 and Hepatic fibrosis: Moreover, serum kallistatin levels are significantly lower in patients with liver fibrosis (49, 50), cirrhosis (50) and alcoholic cirrhosis (51) compared to controls, and decrease further with disease progression (50, 51), indicating it as a useful and reliable diagnostic biomarker for hepatic health.